UNSPSC 51433004: Rilmenidine phosphate

This classification denotes an antihypertensive agent with the molecular formula C10H16N2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59QD64Q32M, chemically known as 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1) but more generally known as rilmenidine dihydrogen phosphate, which bears US NIH Compound Identifier 198614. European Medicines Agency schedules Rilmenidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21586.

Most nations, for tariff and trade purposes, schedule rilmenidine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, RILMENIDINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC1C(C2CC2)NC3=NCCO3.OP(=O)(O)O.

UNSPSC 51433004 Rilmenidine phosphate, a Commodity code, covers prescription and over-the-counter pharmaceutical products procured by state and local health agencies, emergency medical services, and pharmacy benefit programs. State and local governments buy specific medications and drug formulations under this code for use in emergency response, public health programs, and multi-jurisdictional pharmacy benefit initiatives. Issuing bodies include city fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states and participating local jurisdictions. The work involves sealed-bid procurement of manufactured pharmaceuticals with firm pricing, supply-chain compliance documentation, expiration-date management, and vendor performance requirements such as insurance coverage, Good Manufacturing Practice certification, and Drug Supply Chain Security Act compliance.

Recent activity spans Florida, Texas, and the Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a one-year term plus renewal options. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity and value-based pharmacy arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, with contract effectiveness set for July 1, 2026.